61 results
424B3
CRVO
CervoMed Inc
6 Jun 24
Prospectus supplement
6:03am
then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit … to the ANDA or 505(b)(2) applicant. Alternatively, if the listed patent holder does not file a patent infringement lawsuit within the required 45-day period
8-K
EX-10.1
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (2) if, in connection with any lawsuit filed
8-K
EX-10.2
ydvpk4zc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.3
l5pc sycqkbwmnmf
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
1ies7q4 3tkpu
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
rwripf0e
17 Nov 23
Entry into a Material Definitive Agreement
5:03pm
8-K/A
EX-99.3
kjrp7bbr2
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
425
EX-10.1
giy99mp
19 May 23
Business combination disclosure
4:31pm
8-K
EX-10.1
qwp32flvplsx6vd2cal8
19 May 23
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-10.1
1bkd19
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
EX-1.1
f6lfhl4n6
18 Feb 21
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
4:52pm
8-K
EX-10.1
4gqhi6y fkj
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
8-K
EX-10.1
182w2 xuxb23tz9j1
25 Sep 20
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
4:57pm
8-K
EX-10.2
hrd egjjlmaf1j74
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
8-K
EX-10.1
81dmmrzxvulsk0gwt91r
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
8-K
EX-10.1
kyye pemem9t7
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-10.1
8x3sqdx
18 Mar 20
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
5:22pm